Physician profile
Matthew Thomas Williams
NPI 1891392643
$1,758.56
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,112 · 2022: $647.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.22 | 2021-2022 | |
| Novo Nordisk INC | $325.91 | 2021-2022 | |
| Abbvie INC. | $254.61 | 2021-2022 | |
| Esperion Therapeutics, INC. | $204.18 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.65 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $124.97 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $86.79 | 2022 | |
| Glaxosmithkline, LLC. | $44.48 | 2021 | |
| Lilly USA, LLC | $32.57 | 2021-2022 | |
| Astellas Pharma US INC | $30.09 | 2021-2022 | |
| Amarin Pharma, INC. | $29.97 | 2021 | |
| Mylan Specialty L.P. | $21.35 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.64 | 2021 | |
| Horizon Therapeutics Plc | $15.55 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.58 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.